Two weeks until trial results, page-13

I should add that the trading isn't really a thing that I do much.

Almost all my winnings comes from investing in biotechs which I see as undervalued or that have a good chance of a re-rating coming following a successful trial/deal etc.

ftt fits both of these camps atm imho.

A realistic chance of trial success, given what snippets we have seen and the fact that those that respond well to standard care are weeded out. Then there has been less pain reported and drop outs have been exceedingly low.

I can easily come up with a minimum valuation of $300m with success, but there's much upside to that imho.

Cheers